SAG
CNTA

SageView Advisory Group’s Centessa Pharmaceuticals CNTA Stock Holding History

SageView Advisory Group’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10
Closed -$251 – 966
2025
Q4 		$251 Buy
+10
New +$253 ﹤0.01% 2503

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

SageView Advisory Group's CNTA Position: Q1 2026 in Review

SageView Advisory Group sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 10 shares — an estimated $251 sold.

SageView Advisory Group first reported a position in CNTA in Q4 2025 and held it in 1 quarter. The position peaked at $251 in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • SageView Advisory Group reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 10 Centessa Pharmaceuticals shares in Q1 2026, an estimated $251.
  • SageView Advisory Group first reported a position in Centessa Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Centessa Pharmaceuticals position peaked at $251 in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.